Literature DB >> 30376667

Pregnancy-Induced Sweet's Syndrome Treated with Infliximab.

Brigita D Smolovic1, Mirjana D Gajic-Veljic2, Milos M Nikolic2, Damir F Muhovic3.   

Abstract

OBJECTIVE: To present a case of relapsing and resistant Sweet's syndrome that developed during pregnancy together with an onset of Crohn's disease, showing complete resolution with the use of infliximab. CLINICAL PRESENTATION AND INTERVENTION: A 30-year-old pregnant woman presented with fever, skin lesions, and diarrhea. Skin biopsy confirmed neutrophilic dermatosis and she was diagnosed with Crohn's disease after endoscopy. There was no recurrence of Sweet's syndrome outside of her pregnancy. During a previous pregnancy, while corticosteroids were ineffective, complete regression of skin lesions was achieved using infliximab.
CONCLUSION: The "off-label" use of infliximab is beneficial for relapsing and resistant Sweet's syndrome.
© 2018 The Author(s) Published by S. Karger AG, Basel.

Entities:  

Keywords:  Crohn’s disease; Infliximab; Pregnancy; Sweet’s syndrome

Mesh:

Substances:

Year:  2018        PMID: 30376667      PMCID: PMC6545913          DOI: 10.1159/000494974

Source DB:  PubMed          Journal:  Med Princ Pract        ISSN: 1011-7571            Impact factor:   1.927


  10 in total

1.  Regression of Sweet's syndrome associated with Crohn's disease after anti-Tumour Necrosis Factor therapy.

Authors:  J F Rahier; L Lion; O Dewit; M Lambert
Journal:  Acta Gastroenterol Belg       Date:  2005 Jul-Sep       Impact factor: 1.316

2.  Pregnancy-associated Sweet's syndrome in an acute episode of ulcerative colitis.

Authors:  J Best; A Dechene; S Esser; G Gerken; A Canbay
Journal:  Z Gastroenterol       Date:  2009-08-06       Impact factor: 2.000

Review 3.  Tumor necrosis factor biologics beyond psoriasis in dermatology.

Authors:  Raj Patel; John M Cafardi; Nital Patel; Naveed Sami; Jennifer A Cafardi
Journal:  Expert Opin Biol Ther       Date:  2011-06-09       Impact factor: 4.388

4.  Sweet's syndrome associated with myelodysplasia: possible role of cytokines in the pathogenesis of the disease.

Authors:  M A Reuss-Borst; G Pawelec; J G Saal; H P Horny; C A Müller; H D Waller
Journal:  Br J Haematol       Date:  1993-06       Impact factor: 6.998

Review 5.  Inflammatory and glandular skin disease in pregnancy.

Authors:  Catherine S Yang; Mary Teeple; Jennie Muglia; Leslie Robinson-Bostom
Journal:  Clin Dermatol       Date:  2016-02-11       Impact factor: 3.541

Review 6.  The use of infliximab in dermatology.

Authors:  Silja Rott; Ulrich Mrowietz
Journal:  J Dtsch Dermatol Ges       Date:  2007-08       Impact factor: 5.584

Review 7.  Pregnancy-associated Sweet's syndrome: world literature review.

Authors:  P R Cohen
Journal:  Obstet Gynecol Surv       Date:  1993-08       Impact factor: 2.347

8.  Tumor necrosis factor-α and pregnancy complications: a prospective study.

Authors:  Fawaz Y Azizieh; Raj G Raghupathy
Journal:  Med Princ Pract       Date:  2014-12-05       Impact factor: 1.927

9.  Sweet's syndrome associated with Crohn's disease.

Authors:  Caren Dos Santos Lima; Roberta Duarte Bezerra Pinto; Heliana Freitas de Oliveira Góes; Simone de Abreu Neves Salles; Enoi Aparecida Guedes Vilar; Carla Dos Santos Lima
Journal:  An Bras Dermatol       Date:  2017 Mar-Apr       Impact factor: 1.896

Review 10.  Sweet's syndrome--a comprehensive review of an acute febrile neutrophilic dermatosis.

Authors:  Philip R Cohen
Journal:  Orphanet J Rare Dis       Date:  2007-07-26       Impact factor: 4.123

  10 in total
  2 in total

1.  Systematic Review: Sweet Syndrome Associated with Inflammatory Bowel Disease.

Authors:  Joseph Sleiman; Asif A Hitawala; Benjamin Cohen; Katie Falloon; Marian Simonson; Benjamin Click; Urmi Khanna; Anthony P Fernandez; Florian Rieder
Journal:  J Crohns Colitis       Date:  2021-11-08       Impact factor: 9.071

Review 2.  New Practical Aspects of Sweet Syndrome.

Authors:  Tejas P Joshi; Sarah K Friske; David A Hsiou; Madeleine Duvic
Journal:  Am J Clin Dermatol       Date:  2022-02-14       Impact factor: 7.403

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.